Media

Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that its next-generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™. This delivers on the new healthcare product launch milestone prefaced in the FY22 Annual Report and updated in quarterly reports following the closed beta release in June 2022.

Microba Life Sciences (MAP) has signed a distribution agreement with Luminary Health Centers to deliver a consumer microbiome test in the United States. The microbiome test will be powered by Microba’s testing technology and delivered to consumers in the US.

Multibillion-dollar diagnostics services business Sonic Healthcare has acquired a significant minority stake in Microba Life Sciences and struck a strategic partnership with the gut health business. Microba, an ASX-listed small-cap biotech, announced on Tuesday morning that Sonic would invest $17.8 million to acquire a 19.99 per cent stake in the company at 26¢ per share. It is also seeking shareholder approval to acquire options for a further 5 per cent stake.

Sonic takes strategic stake in Microba Giant healthcare stock Sonic Healthcare (ASX:SHL) has bought a stake in small cap Microba Life Sciences (ASX:MAP), sending the MAP share price 60%+ higher this morning. Sonic took a 19.9% stake at 26c a share as it seeks to acquire options for a further 5% stake. Microba focuses on gut health with a revenue-generating business in microbiome testing. The company sells these testing products to healthcare practitioners and gets paid on fee-for-service basis.

Medical diagnostics provider Sonic Healthcare (ASX: SHL) has announced it will spend $17.8 million on the purchase of a 19.99% stake in precision microbiome company Microba Life Sciences (ASX: MAP).

The Australian’s ‘Investor Guide: Health & Biotech FY2023’ featuring Microba Life Sciences.

The GENE Awards is a prestigious event attended by many in the industry – bringing together a number of key life sciences leaders. The GENE Awards featured the presentation of five key industry awards, with 2022 introducing for the first time, the LSQ Company of the Year Award, awarding it to Microba Life Sciences.

MedTech is emerging as an important growth industry for Brisbane. Our state-of-the-art health institutes and research facilities have been an incubator for world-class innovations with the potential to improve patient outcomes and save lives. The MedTech Initiative is about supporting the scale of our local leaders to take their success to the next level.

The Microba Life Sciences (ASX:MAP) share price has risen ~3% in the past five days after the company announced it had expanded its deal with Europe’s largest pathology company SYNLAB (ETR:SYAB).

A partnership between Brisbane-based companies Midnight Health and Microba Life Sciences (ASX: MAP) has borne fruit within five months with the launch of Vidality, a precision prebiotics subscription service for improving the gut microbiome.

Dr Luke Reid recalls his first meeting in 2014 with the founders of Microba Life Sciences (ASX: MAP). At the time, Dr Reid was an Associate Director at UniQuest, a technology transfer company at The University of Queensland. “We believed the biotech market on the ASX had matured significantly and that Microba was well suited to list in this market. Also, we thought Microba had a clear point of difference; there was nothing like our company on the ASX.”

Newly listed Microba Life Sciences (ASX:MAP) has identified three therapeutic leads for the company’s immuno-oncology program, significantly earlier than expected. The company says it will progress to preclinical assessment in 2022, approximately 12 months earlier than expected.

It’s easy to get the impression that the bloke upstairs is trying to knock us all off – one way or the other. Following the pandemic, gastroenteritis has made a strong comeback as we discard masks and return to normal socialisation. But while we’ll be hearing more about nasty tummy bugs – usually from victims staying close to a bucket – spare a thought for the trillions of good ‘germs’ that inhabit the large intestine.

Gut health business Microba is seeking $30 million via an initial public offering and has secured a heavyweight American investor. Microba has developed a kit that allows users to perform a test of their gut microbiome. Microba and its brokers Bell Potter and Canaccord Genuity launched a non deal roadshow on Tuesday, telling investors the book was scheduled to close early next week, ahead of a March ASX listing.

Gut health biotechnology group Microba has landed some big names in its Series B founding round, with Alex Waislitz’s Thorney Investments, Perennial Value and Sydney investment firm Alium Capital backing the 18-month old venture.

Channel 10’s news reader Georgie Lewis presents on the latest gut microbiome testing company to launch in Australia, Microba.

Microba’s launch event was held on Tuesday 17 July 2018 at the Translational Research Institute, with approximately 100 guests attending on the night. Dr Joanna McMillan, one of Australia’s most trusted dietitians hosted the launch event with keynote speeches from Professor Ian Frazer and Dr Jakob Begun and the Hon Dr Anthony Lynham.

Your gut contains trillions of microbes. Brisbane-based Microba wants to use DNA to analyse these microbes to help develop diagnostics and targeted biotherapeutic remedies for diseases such as inflammatory bowel disease, colon cancer, diabetes and depression.

Renowned Queensland scientist Ian Frazer is one of about 30 investors who have raised $7 million for University of Queensland startup company Microba.